Elevated erythropoietin receptor and transforming growth factor-β1 expression in stenotic arteriovenous fistulae used for hemodialysis

Journal of the American Society of Nephrology

Volumn 11, Issue 5, 2000, Pages 928-935

  Ikegaya, Naoki ^a,b   Yamamoto, Tatsuo ^a   Takeshita, Akihiro ^b   Watanabe, Takuya ^a   Yonemura, Katsuhiko ^a   Miyaji, Takehiko ^c   Ohishi, Kazuhisa ^c   Furuhashi, Mitsuyoshi ^c   Maruyama, Yukitaka ^c   Hishida, Akira ^a  

^a First Department of Medicine   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Maruyama Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN RECEPTOR; FIBRONECTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT ERYTHROPOIETIN; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTERIOVENOUS FISTULA; ARTERY INTIMA PROLIFERATION; ARTERY OCCLUSION; ARTICLE; ATHEROSCLEROTIC PLAQUE; CLINICAL ARTICLE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; GENE LOCATION; HEMODIALYSIS; HUMAN; MALE; PRIORITY JOURNAL; THROMBOSIS;

EID: 0034053794     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/asn.v115928     Document Type: Article

References (37)

1. Eschbach JW, Egrie J, Downing M, Browne J, Adamson J: Correction of anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 316: 73-78, 1987
2. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM: Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 2: 1175-1178, 1986
3. Canadian Erythropoietin Study Group: Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Br Med J 300: 573-578, 1990
4. Sundal E, Kaeser U: Correction of anaemia of chronic renal failure with recombinant human erythropoietin: Safety and efficacy of one year's treatment in a European multicenter study of 150 hemodialysis-dependent patients. Nephrol Dial Transplant 4: 979-987, 1989
5. Eschbach JW: Erythropoietin is not a cause of access thrombosis. Semin Dial 6: 180-184, 1993
6. Marchi SD, Cecchin E, Falleti E, Giacomello R, Stel G, Sepiacci G, Bortolotti N, Zanello F, Gonano F, Bartoli E: Long-term effects of erythropoietin therapy on fistula stenosis and plasma concentrations of PDGF and MCP-1 in hemodialysis patients. J Am Soc Nephrol 8: 1147-1156, 1997
7. Muirhead N: Erythropoietin is a cause of access thrombosis. Semin Dial 6: 184-188, 1993
8. Churchill DN, Muirhead N, Goldstein M, Posen G, Fay W, Beecroft ML, Gorman J, Taylor W: Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant human erythropoietin. J Am Soc Nephrol 4: 1809-1813, 1994
9. Fan PY, Schwab SJ: Vascular access: Concepts for the 1990s. J Am Soc Nephrol 3: 1-11, 1992
10. Windus DW: Permanent vascular access: A nephrologist's view. Am J Kidney Dis 21: 457-471, 1993
11. Sukhatme VP: Vascular access stenosis: Prospects for prevention and therapy. Kidney Int 49: 1161-1174, 1996
12. Swedberg SH, Brown BG, Sigley R, Wight TN, Gordon D, Nicholls SC: Intimai fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patients. Circulation 80: 1726-1736, 1989
13. Rekhter M, Nicholls S, Ferguson M, Gordon D: Cell proliferation in human arteriovenous fistulae used for hemodialysis. Arterioscler Thromb 13: 609-617, 1993
14. Hofstra L, Tordoir JHM, Kitslaar PJEHM, Hoeks APG, Daemen MJAP: Enhanced cellular proliferation in intact stenotic lesions derived from human arteriovenous fistulae and peripheral bypass grafts: Does it correlate with flow parameters? Circulation 94: 1283-1290, 1996
15. Ross R: The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362: 801-809, 1993
16. Iseki K, Nishime K, Uehara H, Tokuyama K, Toma S, Yoshihara K, Kowatari T, Terukina S, Oswa A, Fukiyama K: Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients. Nephron 72: 30-36, 1996
17. Border WA, Ruoslahti E: Transforming growth factor-β in disease: The dark side of tissue repair. J Clin Invest 90: 1-7, 1992
18. Nabel EG, Shum L, Pompili VJ, Yang ZY, San H, Shu HB, Liptay S, Gold L, Gordon D, Derynck R, Nabel GJ: Direct transfer of transforming growth factor-β gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci USA 90: 10759-10763, 1993
19. Wolf YW, Rasmussen LM, Ruoslahti E: Antibodies against transforming growth factor-β1 suppress intimai hyperplasia in a rat model. J Clin Invest 93: 1172-1178, 1994
20. Zhang Z, Barrett JD, Zhu JH, Lee DBN, Ward HJ, Jamgotchian N, Hu MS, Eggena P: Erythropoietin (RhEPO) upregulates angiotensin receptors: Further studies on the mechanism of RhEPO hypertension [Abstract]. J Am Soc Nephrol 7: 1545, 1996
21. Nagai T, Akizawa T, Kohjiro S, Koiwa F, Nabeshima K, Niikura K, Kino K, Kanamori N, Kinugasa E, Ideura T: rHuEpo enhances the production of plasminogen activator inhibitor-1 in cultured endothelial cells. Kidney Int 50: 102-107, 1996
22. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M: Erythropoietin has a mitogenic and positive chemotactic effect on endothehal cells. Proc Natl Acad Sci USA 87: 5978-5982, 1990
23. Gogusev J, Zhu DL, Hærembert T, Ammarguellat F, Marche P, Drueke T: Effect of erythropoietin on DNA synthesis, protooncogene expression and phospholipase C activity in rat vascular smooth muscle cells. Biochem Biophys Res Commun 199: 977-983, 1994
24. Miller DA Lee A, Matsui Y, Chen EY, Moses HL, Derynck R: Complementary DNA cloning of the murine transforming growth factor-beta 3 (TGF-beta 3) precursor and the comparative expression of TGF beta 3 and 1 messenger RNA in murine embryos and adult tissues. Mol Endocrinol 3: 1926-1934, 1989
25. Yamamoto T, Noble NA, Cohen AH, Nast CC, Hishida A, Gold LI, Border WA: Expression of transforming growth-factor-β isoforms in human glomerular diseases. Kidney Int 49: 461-469, 1996
26. Shinjyo K, Takeshita A, Higuchi M, Ohnishi K, Ohno R: Erythropoietin receptor expression on human bone marrow erythroid precursor cells by a newly devised quantitative flow-cytometric assay. Br J Haematol 96: 942-950, 1997
27. Gabius HJ, Andre S, Danguy A, Kayser K, Gabius S: Detection and quantification of carbohydrate-binding sites on cell surfaces and in tissue sections by neoglycoproteins. Methods Enzymol 242: 37-46, 1994
28. van Geet C, Hauglustaine D, Verresen L, Vanrusselt M, Vermylen J: Haemostatic effects of recombinant human erythropoietin in chronic haemodialysis patients. Thromb Haemost 61: 117-121, 1989
29. Huraib S, Al-Momen AK, Gader AMA, Mitwalli A, Sulimani E, Abu-Aisha H: Effect of recombinant human erythropoietin (rHuEpo) on the hemostatic system in chronic hemodialysis patients. Clin Nephrol 36: 252-257, 1991
30. Kaupke CJ, Butler GC, Vaziri ND: Effect of recombinant human erythropoietin on platelet production in dialysis patients. J Am Soc Nephrol 3: 1672-1679, 1993
31. Cases A, Escolar G, Reverter JC, Ordinas A, Lopez J, Revert L, Castillo R: Recombinant human erythropoietin improves platelet function in uremic patients. Kidney Int 42: 668-672, 1992
32. Krantz SB: Erythropoietin. Blood 77: 419-434, 1991
33. Schmieder RE, Langenfeld MRW, Hilgers KF: Endogenous erythropoietin correlates with blood pressure in essential hypertension. Am J Kidney Dis 29: 376-382, 1997
34. Vassalli J, Sappino A, Belin D: The plasminogen activator/ plasmin system. J Clin Invest 88: 1067-1072, 1991
35. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ: Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 89: 6998-7002, 1992
36. Lupu F, Bergonzelli GE, Heim DA, Cousin E, Genton CY, Bachmann F, Kruithof EK: Localization and production of plasminogen activator inhibitor 1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 13: 1090-1100, 1993
37. Caelini RG, Reyes AA, Rothstein M: Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int 47: 740-745, 1995